Retrospective assessment of HDR brachytherapy dose calculation methods in locally advanced cervical cancer patients: AcurosBV vs. AAPM TG43 formalism
Open Access
- 9 October 2024
- journal article
- research article
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (1) , e14549
Abstract
Purpose: This retrospective analysis was completed to investigate the use of a model‐based dose calculation algorithm (MBDCA) AcurosBV, for use in HDR BT treatments for locally advanced cervical cancer treated with tandem and ovoid applicators with interstitial needles.Methods: A cohort of 32 patients receiving post‐EBRT HDR brachytherapy boost with a prescription dose of 5.5 Gy × 5 fractions to the high‐risk clinical target volume (CTVHR) were selected for this study. For standard TG43 dose calculation, applicators were manually digitized on the planning images, while for AcurosBV calculations, solid renderings of Titanium Fletcher Suite Delclos (FSD) applicators included in BrachyVision were matched to those used clinically and Ti needles were manually digitized. The dose was recalculated using Varian's AcurosBV 13.5 and dose‐to‐medium‐in‐medium (Dm,m) was reported. EQD2 values for targets and organs at risk were compared between dose calculation formalisms. D90% and D98% values were reported for the high and intermediate‐risk CTVs, and values were reported for OARs including bladder, rectum, sigmoid, bowel, and vagina. Due to variability within the patient cohort, the dosimetric impact of AcurosBV was investigated corresponding to planning image modality (CT vs. CBCT), presence of Ti needles, and contrast within vaginal balloons used to stabilize implants. AcurosBV showed lower dosimetric values for all plans compared to TG43.Results: The average ± standard deviation of dosimetric reduction in D90% was 4.33 ± 0.09% for CTVHR and 4.12 ± 0.09% for CTVIR. The reduction to OARs was: 4.99 ± 0.15% for bladder, 7.87 ± 0.16% for rectum, 5.79 ± 0.17% for sigmoid, 6.91 ± 0.14% for bowel, and 4.55 ± 0.14% for vagina.Conclusions: AcurosBV should be utilized for HDR BT GYN cases, treated with tandem and ovoid applicators, with high degrees of heterogeneity and calculated in tandem with TG43.Keywords
This publication has 18 references indexed in Scilit:
- Dosimetric comparison of AcurosBV with AAPM TG43 dose calculation formalism in cervical intraductal high‐dose‐rate brachytherapy using three different applicatorsPrecision Radiation Oncology, 2022
- Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice GuidelinePractical Radiation Oncology, 2020
- Model-Based Dose Calculation Algorithms for Brachytherapy DosimetrySeminars in Radiation Oncology, 2020
- The validity of Acuros BV and TG-43 for high-dose-rate brachytherapy superficial mold treatmentsBrachytherapy, 2017
- International Commission on Radiation Units and MeasurementsJournal of the ICRU, 2014
- Trends in the Utilization of Brachytherapy in Cervical Cancer in the United StatesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- The dosimetric impact of heterogeneity corrections in high-dose-rate 192Ir brachytherapy for cervical cancer: Investigation of both conventional Point-A and volume-optimized plansBrachytherapy, 2012
- Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapyRadiotherapy and Oncology, 2012
- Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculationsMedical Physics, 2004
- rather than should be used in Monte Carlo treatment planningMedical Physics, 2002